Revvity, Inc. (RVTY) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Revvity, Inc. (RVTY) Healthcare & Pipeline Overview

Revvity, Inc., formerly PerkinElmer, is a global provider of diagnostics, life sciences, and applied services solutions. Operating through two segments, the company offers instruments, reagents, software, and services to research institutions, pharmaceutical companies, and healthcare organizations. With a focus on innovation, Revvity supports advancements in genetic disorder detection and scientific research.

What Is the Investment Thesis for RVTY?

Revvity, Inc. presents a notable research candidate within the healthcare sector, driven by its diversified revenue streams across diagnostics and life sciences. With a market capitalization of $12.6B and a P/E ratio of 40.6, the company demonstrates a solid financial foundation. A gross margin of 51.4% and a profit margin of 8.3% indicate efficient operations. Key growth catalysts include expanding its diagnostic solutions and increasing its presence in the applied services market. The company's focus on innovative technologies and strategic partnerships should drive long-term value. However, potential risks include competition from established players and regulatory challenges in the healthcare industry. Revvity's beta of 1.13 suggests moderate volatility compared to the market.

Based on FMP financials and quantitative analysis

RVTY Key Highlights

• Market Cap of $12.6B reflects substantial investor confidence in Revvity's market position.
• P/E Ratio of 40.6 indicates investors are willing to pay a premium for Revvity's earnings, reflecting growth expectations.
• Gross Margin of 51.4% demonstrates efficient cost management and strong pricing power.
• Profit Margin of 8.3% shows Revvity's ability to convert revenue into profit after all expenses.
• Dividend Yield of 0.28% provides a modest income stream for investors, enhancing total return.

Who Are RVTY's Competitors?

RVTY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are RVTY's Key Strengths?

• Diversified product portfolio across diagnostics and life sciences.
• Strong brand reputation and established customer relationships.
• Innovative technologies and focus on R&D.
• Global presence and extensive distribution network.

What Are RVTY's Weaknesses?

• High P/E ratio may indicate overvaluation.
• Dependence on regulatory approvals for new products.
• Exposure to competition from larger, more established players.
• Potential for product liability claims.

What Could Drive RVTY Stock Higher?

• New product launches in the diagnostics segment, expanding testing capabilities.
• Expansion of genomic sequencing services, driving revenue growth.
• Strategic partnerships and acquisitions, broadening market reach.
• Increasing demand for environmental monitoring services, boosting revenue in the applied services market.

What Are the Key Risks for RVTY?

• Rich valuation — a P/E of 40.6 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
• Changes in healthcare regulations and reimbursement policies, impacting revenue.
• Technological obsolescence, requiring continuous innovation.
• Competition from larger, more established players, limiting market share.
• Economic downturns and reduced healthcare spending, affecting demand for products and services.

What Are the Growth Opportunities for RVTY?

• Expansion in Genomic Sequencing: Revvity can leverage its technologies in next-generation DNA sequencing to capitalize on the growing market for genomic sequencing in oncology, immunodiagnostics, and drug discovery. The global genomic sequencing market is projected to reach $25 billion by 2028, offering substantial growth potential. Revvity's expertise in this area provides a competitive advantage, enabling it to capture a significant share of this expanding market.
• Growth in Diagnostics Segment: The Diagnostics segment offers significant growth opportunities through the development and commercialization of new diagnostic tests for genetic disorders and infectious diseases. The increasing prevalence of genetic disorders and the need for early detection drive demand for these tests. Revvity's focus on innovation and its established distribution channels position it to capitalize on this growth, with potential for increased revenue and market share.
• Penetration of Applied Services Market: Revvity's Discovery & Analytical Solutions segment can further penetrate the applied services market by offering analytical technologies and services for monitoring air, water, and soil health. With increasing environmental concerns and regulatory requirements, the demand for these services is growing. Revvity's solutions for farmers, food producers, and industrial clients provide a strong foundation for expanding its presence in this market.
• Strategic Partnerships and Acquisitions: Revvity can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. Collaborations with other companies in the diagnostics and life sciences sectors can accelerate innovation and provide access to new technologies. Targeted acquisitions can complement Revvity's existing capabilities and expand its presence in key markets, driving long-term growth and value creation.
• Expansion in Emerging Markets: Emerging markets offer significant growth opportunities for Revvity, driven by increasing healthcare spending and growing demand for diagnostic and life sciences solutions. By expanding its presence in these markets, Revvity can tap into new customer segments and diversify its revenue streams. Strategic investments in distribution networks and local partnerships can facilitate market entry and drive sustainable growth in these regions.

What Opportunities Does RVTY Have?

• Expansion in emerging markets.
• Strategic partnerships and acquisitions.
• Growth in genomic sequencing and personalized medicine.
• Increasing demand for diagnostic testing and life sciences research.

What Threats Does RVTY Face?

• Changes in healthcare regulations and reimbursement policies.
• Technological obsolescence.
• Economic downturns and reduced healthcare spending.
• Competition from new entrants and disruptive technologies.

What Are RVTY's Competitive Advantages?

• Proprietary technologies and intellectual property.
• Established relationships with key customers.
• Extensive distribution network.
• Strong brand reputation in the diagnostics and life sciences markets.

What Does RVTY Do?

Revvity, Inc., established in 1937 and formerly known as PerkinElmer, Inc., is a global corporation providing products, services, and solutions to the diagnostics, life sciences, and applied services markets. Headquartered in Waltham, Massachusetts, Revvity operates through two primary segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a range of instruments, reagents, informatics, software, and detection technologies. These tools enable scientists to accelerate research in life sciences, while also providing contract research and laboratory services. This segment extends its reach to analytical technologies for monitoring air, water, and soil health, catering to farmers, food producers, and industries like chemical, semiconductor, energy, and petrochemical. The Diagnostics segment focuses on early detection of genetic disorders and infectious disease testing, providing instruments, reagents, assay platforms, and software. Its products are essential for screening and testing genetic abnormalities, including Down syndrome, hypothyroidism, and muscular dystrophy. Additionally, this segment develops technologies for genomic workflows, utilizing protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery applications. Revvity serves a diverse clientele, including pharmaceutical and biotechnology companies, laboratories, academic institutions, public health authorities, healthcare organizations, and government agencies. The company rebranded as Revvity, Inc. in April 2023, marking a new chapter in its evolution.

What Products and Services Does RVTY Offer?

• Develop and manufacture instruments for life sciences research.
• Provide diagnostic solutions for early detection of genetic disorders.
• Offer analytical technologies for environmental monitoring.
• Supply reagents and assay platforms for various testing applications.
• Provide informatics and software solutions for data analysis.
• Offer contract research and laboratory services.
• Support genomic workflows using next-generation DNA sequencing.

How Does RVTY Make Money?

• Sale of instruments, reagents, and software to research institutions and diagnostic laboratories.
• Recurring revenue from subscriptions and service contracts.
• Revenue from contract research and laboratory services.
• Licensing of technologies and intellectual property.

What Industry Does RVTY Operate In?

Revvity, Inc. operates in the rapidly evolving medical diagnostics and life sciences industry. The market is driven by increasing demand for early disease detection, personalized medicine, and advanced research tools. The competitive landscape includes companies like Exact Sciences Corporation (EXAS), Align Technology, Inc. (ALGN), and Guardant Health, Inc. (GH). Revvity's diversified portfolio and focus on innovation position it well to capitalize on industry growth trends, including the expansion of genomic sequencing and the increasing adoption of diagnostic technologies in emerging markets.

Who Are RVTY's Key Customers?

• Pharmaceutical and biotechnology companies.
• Academic and research institutions.
• Public health authorities.
• Private healthcare organizations and hospitals.

FY2026 estForward Outlook

Wall Street analysts project Revvity, Inc. revenue of about $2.83B for fiscal 2026, with EPS near $5.24. The estimate reflects 9 contributing analysts.

ROE 3%Key Financial Metrics

Return on equity for Revvity, Inc. stands at 3.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.0%, showing how much profit it generates from its asset base. RVTY trades at a trailing price-to-earnings ratio of 40.61, above the Healthcare sector average of ~23x. Its free cash flow yield is 4.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.72 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 1.9%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 7/9Financial Health

Revvity, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.68 places it in the grey zone, a middle ground that warrants monitoring.

RVTY Valuation & Market Position

With a $12.6B market cap, Revvity, Inc. sits in the large-cap segment of the market. Relative to its peer group, RVTY's quantitative score of 65/100 is roughly in line with the peer average of 58/100.

RVTY Financials

RVTY Latest News

RVTY Analyst Consensus

RVTY MoonshotScore

Revvity, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources